Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Revenue (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Revenue for 4 consecutive years, with $57.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 94.12% to $57.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $175.1 million, a 216.93% increase, with the full-year FY2025 number at $175.1 million, up 216.93% from a year prior.
  • Revenue was $57.6 million for Q4 2025 at Phathom Pharmaceuticals, up from $49.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $57.6 million in Q4 2025 to a low of -$9.6 million in Q4 2022.
  • A 4-year average of $15.7 million and a median of $7.3 million in 2024 define the central range for Revenue.
  • Peak YoY movement for Revenue: skyrocketed 4249.56% in 2024, then soared 94.12% in 2025.
  • Phathom Pharmaceuticals' Revenue stood at -$9.6 million in 2022, then skyrocketed by 107.1% to $682000.0 in 2023, then surged by 4249.56% to $29.7 million in 2024, then soared by 94.12% to $57.6 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Revenue are $57.6 million (Q4 2025), $49.5 million (Q3 2025), and $39.5 million (Q2 2025).